The tirzepatide dosage chart explained: what each step means

What does each step on the tirzepatide dosage chart actually do?

The chart you'll find on the tirzepatide dose chart overview reflects the schedule set out in the licensed prescribing information for Mounjaro in the UK. There are six strengths, and they run in 2.5 mg increments: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Treatment always begins at 2.5 mg regardless of your starting weight. That first pen's job is adjustment, giving your digestive system time to get used to a drug that slows gastric emptying and changes how hunger signals reach the brain.

After four weeks at 2.5 mg, your prescriber reviews your experience and, if things are going well, increases the dose to 5 mg. From there, the same four-week minimum applies at each rung. The intent is to reach the lowest dose that produces meaningful, sustained weight loss for you personally, which may be 7.5 mg, 10 mg, or higher. Hitting 15 mg is not the target; tolerating and responding well to your dose is. The Mounjaro dosage chart maps exactly this sequence because Mounjaro is the brand name for tirzepatide in the UK.

One practical detail worth knowing: each KwikPen contains four doses, one for each week of that strength's step. Keep it in the fridge door, away from the freezer section, until you're ready to use it. Exact storage temperature limits are set out in the Patient Information Leaflet that comes with your pen, always refer there rather than relying on a third-party summary.

Is a tirzepatide dosage chart in ml useful, and what does volume tell you?

Some people search for a tirzepatide weekly dosage chart in millilitres rather than milligrams, often because they've seen dosing information for compounded semaglutide or unlicensed versions elsewhere. For the licensed Mounjaro KwikPen, the volume delivered per injection is fixed and consistent across pens, you don't draw up a syringe or measure ml. The pen injects a pre-set amount each time you press the button.

What actually matters clinically is the milligram strength, not the liquid volume. A tirzepatide dosage chart in ml is therefore not a document your prescriber uses, and converting between ml and mg without knowing the concentration of a specific preparation is unreliable. If you've encountered a chart showing ml values, it is almost certainly referencing an unlicensed compounded product, not a Mounjaro KwikPen. The NHS patient information for tirzepatide confirms the pen-based delivery format and the mg strengths that apply to the UK-licensed medicine.

This distinction matters for safety. Counterfeit and unlicensed products have been seized in large quantities by the MHRA, some containing substances other than tirzepatide. The only dosage chart that applies to genuine Mounjaro is the one in the licensed prescribing information, which works in milligrams and doesn't ask you to measure anything.

When does the prescriber decide to hold, reduce, or skip a dose increase?

The standard schedule is a guide, not a fixed contract. A prescriber may hold a patient at their current strength for longer than four weeks if side effects haven't settled, if weight response is already strong, or if there's a clinical reason to move carefully. The chart shows the ceiling and the sequence; it doesn't dictate the pace for any individual.

Dose reductions are also possible. If side effects at a higher strength are persistent or uncomfortable, dropping back temporarily is a legitimate clinical decision. The 10 mg dose in particular is where some people find they need a little longer to adapt before moving further. None of this is unusual, it's the kind of individualised decision that makes prescriber-led treatment different from following a generic chart.

What this means in practice is that missed doses, timing questions, and anything that changes the four-week rhythm should always go back to your prescriber rather than being worked out from the chart alone. The BNF's clinical reference for tirzepatide and the prescribing SmPC on the eMC both reserve those specifics for the prescriber-patient conversation. For a broader look at how tirzepatide dosing decisions are made, that page goes further into the clinical reasoning behind the schedule.

How does the dosage schedule connect to eligibility and what to expect?

Understanding the chart also helps set realistic expectations. The 2.5 mg starting dose produces little weight loss on its own, that's normal and expected. Weight reduction typically becomes more noticeable from 5 mg upwards, building as the schedule progresses. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants on the highest dose saw average body-weight reductions of around 20–21% over 72 weeks, figures that come from sustained, titrated use at therapeutic strengths, not from the starter dose.

For weight management in the UK, tirzepatide is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, raised cholesterol, or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. NICE's appraisal of tirzepatide (TA1026) sets out the NHS eligibility criteria, which are currently more restrictive than the licensed indication. Private prescribing (through a service like the route available at nume) follows the licensed criteria, with full clinical assessment at each stage.

If you're weighing up whether tirzepatide is the right fit, the Mounjaro overview covers the broader picture, including how the dual GIP and GLP-1 mechanism compares to single-receptor alternatives. For a sense of what private treatment costs, the Mounjaro pricing page gives honest context without requiring you to commit to anything first.